Injection emulsion containing breviscapinum and preparation method thereof

Abstract

The invention relates to an emulsion injection containing Breviscapine and its preparing process, which is prepared from the following raw materials (by weight portion): Breviscapine 0.01-0.04%, oil for injection 5-30%, emulsifying agent 1-5%, isotonic agent 2-10%, stabilizer 0.1-8% and balancing water for injection. The preparation process comprises the steps of proportioning, making oily phase mixture, making initial milk, emulsifying and sterilizing.

Description

technical field [0001] The invention relates to a medicine for preventing and treating ischemic and hemorrhagic cerebrovascular sequelae, and treating cardiovascular and cerebrovascular diseases, specifically an injection emulsion containing breviscapine; the invention also relates to the production of the injection emulsion containing breviscapine method. technical background [0002] Breviscapus is a total flavonoid extracted from Erigeron breviscapus (Vant.) Hand-Mazz plant of Compositae, more than 90% of which is scutellarin, which can expand microvessels, improve microcirculation, Improve myocardial function and blood supply to the heart and brain, reduce blood viscosity, inhibit platelet aggregation, prevent thrombosis and thrombolysis, and lower blood lipids. At present, the clinical application of breviscapine is mainly small injections, but it is found in clinical application that low doses of breviscapine are not effective, and only large doses of breviscapine can...

AI Technical Summary

Problems solved by technology

At present, the clinical application of breviscapine is mainly small injections, but it is found that low doses of breviscapine are not effective, and only large doses of breviscapine can be effective

In clinical application, many small needles need to be sawn open and then poured into normal saline or glucose injection for intravenous infusion, which is not only troublesome to operate, but also more likely to cause secondary pollution

In addition, although the breviscapine freeze-dried preparations that have been on the market have greatly improved their stability, they require high production conditions and are more inconvenient to use. In clinical use, the ampoule bottle needs to be sawed open and then injected with water for injection or physiological Vibrate with saline and then add normal saline or glucose injection for infusion

[0003] The main component of breviscapine, scutellarin, is unstable and easily deteriorates during storage. Currently, all breviscapine injections in clinical use have such problems. Therefore, it is urgent to solve the problem of the stability of breviscapine.

Images